NCT04479631

Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196

A Phase 1 Randomized, Single-blind, Placebo-controlled, Single Ascending Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Human Monoclonal Antibody, BRII-196 Administered Intravenously to Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Brii Biosciences Limited · Industry
• Sex: All
• Age: 18 Years – 49 Years
• Healthy volunteers: Accepted

Summary

This is a phase 1 study in which healthy adult volunteers will receive BRII-196 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	BRII-196	BRII-196 given intravenously
DRUG	Placebo	Placebo given intravenously

Timeline

• Start date: 2020-07-12
• Primary completion: 2021-01-29
• Completion: 2021-01-29
• First posted: 2020-07-21
• Last updated: 2023-03-03

Locations

1 site across 1 country: China